UPDATE: Goldman Sachs Upgrades Abbott Laboratories; Growth Is Poised To Accelerate

In a report published Sunday, Goldman Sachs analyst David H. Roman upgraded the rating on Abbott Laboratories (NYSE: ABT ) from Neutral to Buy and raised the price target on the company from $38.00 to $44.00. In the report, Goldman Sachs noted, "(1) Emerging markets growth is taking hold faster